Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Rothschild & Co Redburn Adjusts Price Target on CRH public to $120 From $135, Keeps Buy Rating

Rothschild & Co Redburn Adjusts Price Target on CRH public to $120 From $135, Keeps Buy Rating

MT newswireMT newswire2026/10/01 13:42
09:42 AM EDT, 10/01/2026 (MT Newswires) -- CRH public company (CRH) has an average rating of buy and mean price target of $134.39, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us) Price: 82.01, Change: -0.78, Percent Change: -0.94
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

South Korea’s current account surplus in September exceeded 60 billions USD for the first time, with semiconductor exports becoming the main driver

Driven by booming semiconductor exports, South Korea's current account surplus in September surged to a record high.

智通财经•2026/11/05 02:41
South Korea’s current account surplus in September exceeded 60 billions USD for the first time, with semiconductor exports becoming the main driver

CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading

CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

智通财经•2026/11/05 01:51
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response

According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.

智通财经•2026/11/05 01:36

Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test

Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).

智通财经•2026/11/05 01:07
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test